Alx Oncology Holdings (ALXO) Times Interest Earned (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Times Interest Earned of -$4.94 for Q1 2026, up 93.69% on a YoY basis from -$2.55 in Q1 2025, and up 86.56% sequentially from -$36.77 in Q4 2025.
Alx Oncology Holdings (ALXO) Times Interest Earned (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Times Interest Earned data on file, last reported at -$4.94 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned rose 93.69% year-over-year to -$4.94; the trailing twelve-month figure through Mar 2026 stood at -$23.77 (up 64.1% YoY), and the FY2025 full-year result was -$0.69, up 96.59% from the prior year.
- Times Interest Earned grew to -$4.94 in Q1 2026, from -$36.77 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$4.94 in Q1 2026 to a low of -$18340.5 in Q3 2022.
- A 5-year average of -$2141.1 and a median of -$83.21 in 2023 frame the typical range for Times Interest Earned.
- Across the five-year window, Times Interest Earned tumbled 96919.77% in 2022 and surged 99.41% in 2023, its largest moves.
- Tracing ALXO's Times Interest Earned over 5 years: stood at -$139.48 in 2022, then surged by 45.69% to -$75.75 in 2023, then jumped by 48.25% to -$39.2 in 2024, then grew by 6.18% to -$36.77 in 2025, then surged by 86.56% to -$4.94 in 2026.
- Business Quant data shows ALXO's Times Interest Earned at -$4.94 in Q1 2026, -$36.77 in Q4 2025, and -$55.23 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -4.94 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.94 |
| Dec 31, 2025 | -36.77 |
| Sep 30, 2025 | -55.23 |
| Jun 30, 2025 | -11.10 |
| Mar 31, 2025 | -78.37 |
| Dec 31, 2024 | -39.20 |
| Sep 30, 2024 | -73.02 |
| Jun 30, 2024 | -96.79 |
| Mar 31, 2024 | -88.44 |
| Dec 31, 2023 | -75.75 |
| Sep 30, 2023 | -136.25 |
| Jun 30, 2023 | -98.86 |
| Mar 31, 2023 | -83.21 |
| Dec 31, 2022 | -139.48 |
| Sep 30, 2022 | -18,340.50 |
| Jun 30, 2022 | -16,894.50 |
| Mar 31, 2022 | -146.43 |
| Dec 31, 2021 | 222.44 |
| Sep 30, 2021 | -133.57 |
| Jun 30, 2021 | -17.41 |